Robert J Hogan Selected Research

Type V Secretion Systems

4/2019	The autotransporter protein BatA is a protective antigen against lethal aerosol infection with Burkholderia mallei and Burkholderia pseudomallei.
1/2017	Antibodies against In Vivo-Expressed Antigens Are Sufficient To Protect against Lethal Aerosol Infection with Burkholderia mallei and Burkholderia pseudomallei.
1/2015	The Autotransporter BpaB Contributes to the Virulence of Burkholderia mallei in an Aerosol Model of Infection.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Robert J Hogan Research Topics

Disease

17	Infections 01/2021 - 11/2005
5	Human Influenza (Influenza) 01/2021 - 11/2002
5	Glanders 12/2020 - 01/2013
4	Virus Diseases (Viral Diseases) 07/2022 - 01/2002
4	Severe Acute Respiratory Syndrome 01/2008 - 07/2004
3	COVID-19 10/2021 - 11/2020
3	Melioidosis 01/2017 - 01/2013
2	Pneumonia (Pneumonitis) 01/2013 - 07/2007
2	Influenza in Birds (Avian Flu) 01/2013 - 03/2010
1	Acquired Immunodeficiency Syndrome (AIDS) 01/2017
1	Mumps 07/2013
1	Persistent Infection 01/2013
1	Otitis Media 01/2013
1	Bacteremia 01/2013
1	Communicable Diseases (Infectious Diseases) 01/2013
1	Acute Disease 01/2013
1	Rabies (Hydrophobia) 08/2010
1	Asthma (Bronchial Asthma) 04/2009
1	Filoviridae Infections 11/2005
1	Ebola Hemorrhagic Fever 11/2005
1	Inflammation (Inflammations) 10/2004
1	Lung Diseases (Lung Disease) 10/2004

Drug/Important Bio-Agent (IBA)

11	VaccinesIBA 10/2021 - 01/2002
8	Proteins (Proteins, Gene)FDA Link 07/2022 - 07/2004
7	AerosolsIBA 12/2020 - 01/2013
7	AntibodiesIBA 12/2020 - 03/2006
4	AntigensIBA 04/2019 - 01/2002
3	Type V Secretion SystemsIBA 04/2019 - 01/2015
3	Hemagglutinins (Hemagglutinin)IBA 01/2019 - 03/2010
3	Anti-Bacterial Agents (Antibiotics)IBA 01/2018 - 01/2013
2	Pharmaceutical PreparationsIBA 07/2022 - 11/2020
2	Immunoglobulin G (IgG)IBA 01/2017 - 11/2002
2	Neutralizing AntibodiesIBA 02/2011 - 07/2004
2	EpitopesIBA 08/2010 - 07/2004
2	InterferonsIBA 01/2008 - 10/2004
1	Probenecid (Benemid)FDA LinkGeneric 10/2021
1	Messenger RNA (mRNA)IBA 01/2021
1	RNA (Ribonucleic Acid)IBA 01/2021
1	Complement System Proteins (Complement)IBA 12/2020
1	Peptide Hydrolases (Proteases)FDA Link 11/2020
1	KetonesIBA 11/2020
1	LigandsIBA 11/2020
1	Pattern Recognition ReceptorsIBA 01/2019
1	Virulence Factors (Pathogenicity Factors)IBA 01/2018
1	TrypsinIBA 01/2015
1	Viral AntigensIBA 07/2013
1	SoilIBA 01/2013
1	Conjugate VaccinesIBA 01/2013
1	Interferon-alpha (Interferon Alfa)IBA 02/2011
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 04/2009
1	NF-kappa B (NF-kB)IBA 04/2009
1	Neuraminidase (Sialidase)IBA 05/2008
1	AlbuminsIBA 01/2008
1	Viral RNAIBA 01/2008
1	albumin interferonIBA 01/2008
1	Adenovirus VaccinesIBA 07/2007
1	Influenza A virus M2 proteinIBA 03/2007
1	A-Form DNA (A-DNA)IBA 03/2007
1	Immunoglobulin A (IgA)IBA 11/2002
1	Immunoglobulin M (IgM)IBA 11/2002
1	Lymphotoxin-alpha (Lymphotoxin)IBA 11/2002
1	Peptides (Polypeptides)IBA 11/2002

Therapy/Procedure

5	Therapeutics 10/2021 - 11/2005